Physician profile
Danielle L Bouchard
NPI 1396261863
$3,589.91
in general payments reported to CMS, 2019-2025
22 companies · $1,628 in 2025
The $1,628 reported for 2025 was more than what 93% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $183 · 2023: $383 · 2024: $1,282 · 2025: $1,628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,292.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $609.28 | 2021-2025 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $277.10 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Novartis Pharmaceuticals Corporation | $268.41 | 2022-2025 | |
| Amgen INC. | $244.85 | 2024-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $233.24 | 2024-2025 | Farxiga |
| Novo Nordisk INC | $231.92 | 2024-2025 | Wegovy, Ozempic |
| Alnylam Pharmaceuticals INC. | $225.00 | 2022-2025 | Onpattro, Amvuttra |
| Merck Sharp & Dohme LLC | $210.42 | 2023-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.80 | 2023-2025 | Jardiance |
| Pfizer INC. | $203.41 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $140.09 | 2023-2025 | Lifevest |
| Bridgebio Pharma, INC. | $131.71 | 2025 | Attruby |
| Janssen Pharmaceuticals, INC | $98.47 | 2021-2024 | Xarelto |
| Boston Scientific Corporation | $84.46 | 2021-2024 | Watchman Flx |
| Scpharmaceuticals INC. | $78.10 | 2024-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $68.24 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $67.02 | 2024 | |
| Esperion Therapeutics, INC. | $62.17 | 2025 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $57.71 | 2024 | Arcalyst |
| Abbott Laboratories | $40.20 | 2024-2025 | Amplatzer Amulet, Proclaim |
| Lilly USA, LLC | $26.75 | 2025 | Mounjaro, Zepbound |
| Medicomp INC | $21.56 | 2025 | Telepatch Cardiac Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Bouchard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.